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Abstract
For enhancing immunogenicity and develop vaccine strategies using peptide based constructs
against HIV-1, a chimeric peptide containing V3 loop and transmembrane sequence of gp41 with
two glycine motifs as spacer was constructed. The V3-gp41, gp41 peptide and p17 and p24 peptides
separately or in a cocktail were entrapped with or without MA729 as an immunoadjuvant in
liposomes or ISCOMs. The immunogenicity, antigen induced T-cell proliferation and cytokine
profiles of various formulations were studied in four different inbred strains of mice of H-2d, H-2b,
H-2k and H-2q haplotypes, keeping alum as a control adjuvant. Both liposomes and ISCOM
preparations elicited high titer and long lasting antibody response (60 days and above). When
compared to the alum formulation, the liposomes co-entrapped with MA729 produced high
antibody levels, comparable with that induced by ISCOMs. Peptide in alum, liposomes and ISCOMs
enhanced both antigen specific IgG2a and IgG2b isotypes and high T-cell stimulation index. Peptide
formulations also induced antibodies with high affinity and in vitro neutralizated the formation of
HIV-1 syncytia. T-cell supernatants contained high levels of IFN-γ and IL-2. Thus formulation in
these adjuvants induced a predominant Th1 like response with MA729 as a versatile novel delivery
vehicle for stimulating the appropriate arm of the immune response that can selectively modulate
MHC class I or MHC class II response. The above peptide can be of wide vaccination interest as a
means to improve immune responses to several other HIV-1 antigens and may serve as candidates
for vaccine development.
Introduction
An important consideration for the development of a syn-
thetic vaccine against acquired immunodeficiency syn-
drome (AIDS) is the use of an immunogen incorporating
selected B-cell and T-cell determinants [1-3] thereby
inducing potent and specific neutralizing antibodies
against HIV, rather than whole virus or viral subunits,
which are known to elicit adverse immunosuppressive,
immuno enhancing and autoimmune responses [4,5].
Epitope based strategies representing selected sequences
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has been developed as a result of understanding the mech-
anism of antigen recognition by B and T cells following its
association with either MHC class I or II molecules. Sev-
eral methods have been attempted to make weak peptides
more immunogenic following co-polymerization, cova-
lent linkage, or collinear synthesis to a Th cell peptide,
synthesis of longer constructs such as multiple antigenic
peptides or of hybrid multiple epitopes [6,7]. Although
these approaches elicited satisfactory humoral response
but variability in antibody response among diverse
genetic individuals has limited the applicability of peptide
based vaccines.
Novel mode of vaccine delivery relies on controlled
release technology and to some extent timed-release deliv-
ery of antigen to mimic booster immunizations. Recently,
adjuvants have been shown to strongly augment cellular
responses to peptide antigens [8-10] by selective induc-
tion of Th1 type of response. A number of antigens
derived from HIV sequences together with various adju-
vants have been tested in several delivery systems.
Although they showed promising results, they are fre-
quently associated with certain limitations such as toxic-
ity, which makes them unsuitable in humans. Their
choice therefore appears to be a crucial factor in determin-
ing the final outcome of the immune response. Presently
known HIV-1 vaccine candidates although effective
against some isolates, are not effective against naturally
occurring virus isolates [11]. The major targets for neutral-
izing antibody and focus of most of the studies are the
envelope glycoprotein. The V3 loop domain (derived
from gp120) forms a major component of most of the
subunit vaccines, which has shown to block HIV infection
in vitro [12] as well as in vivo [13]. In the present study four
immunodominant peptides were selected using
hydrophillicity plots from HIV encoded gp120 (V3 loop),
gp41, p17 and p24 proteins representing conserved
domains. Mice with different genetic backgrounds were
selected to look whether; there is a generalized pattern of
immune response in all the strains with diverse genetic
makeup so as to correlate the response with outbred pop-
ulation. A safe and effective approach adopted is the
inclusion of non-toxic, permissible adjuvants like MA729
(MDP analog). The pattern of antibody and T-cell
response seen in these strains is an indicative of a predom-
inantly CD4+ Th1 type of response. Moreover peptides
derived from different antigenic region of HIV elicit anti-
bodies that are able to neutralize laboratory-adapted virus
in vitro. Our data demonstrate that V3-gp41 peptide in
liposome with adjuvant MA729 gives the best antibody
response. Peptide primed lymphocytes proliferated effi-
ciently in response to soluble synthetic peptides of HIV,
delivered in liposome's (alone or in presence of an adju-
vant MA729) or in ISCOMS. T cell proliferation and
cytokine response to liposome and ISCOMS associated
antigens demonstrated enhanced stimulation of lym-
phocyte proliferative responses with induction of Th1 like
cytokines i.e. IFN-γ and IL-2. Thus an attempt has been
made to produce and develop an immunogen for generat-
ing of high titer and high affinity cytophillic antibodies
using novel delivery systems.
Materials and methods
Mice
6–8 weeks old BALB/c. H-2d, C57BL/6J H-2b, FVB/J H-2q
and CBA/J H-2k were obtained from breeding facilities of
National Institute of Immunology, New Delhi. Each
experimental group consisted of 4–6 animals.
Adjuvant
MDP analog (MA729) was the product of CDRI (Central
Drug Research Institute).
Peptides
1. V3-gp41 – combination of V3 loop (308–322) and
gp41 (593–604) sequence bridged with two glycine
motifs.
(LGLWGCSGKLIC GG KRIHIQGPGRAFVT)
------gp41------ ------V3 loop------
2. gp41 (728–753) –
(DRPEGIEEEGGERDRDRSIRLVNGSL).
3. p17 (114–136) –
(KKAQQAAADTGNRGNSSQVSQNY).
4. p24 (287–307) – (QGPKEPFRDYVDRFYKTLLRA)
All the peptides were synthesized using t-Boc chemistry
on PAM resin by the method of Merrifield [14]. The result-
ing peptides were purified using HPLC and characterized
by amino acid composition and homogeneity of the pep-
tides were assessed by various analytical techniques. All
the peptides were found to be > 95% pure.
Liposomes
Liposome's were prepared according to our reported pro-
tocol [15]. Briefly multilamellar vesicles (MLV's) were pre-
pared composed of phosphatidyl choline, cholesterol and
phosphatidyl glycerol taken in molar ratio of 7:4:1. MLV's
were probe sonicated to small unilamellar vesicles
(SUV's). Peptide or peptide with adjuvant at 5 mg/ml was
freeze dried with SUV's. After rehydration and suspending
in PBS, liposomes were pelleted at 100,000 × g. The
amount of peptide antigen entrapped within liposomes
was measured using I125 peptide. The percent efficiency
was found to be in the range of 25–30%.Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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ISCOMs
ISCOMs were prepared according to our reported proto-
col [15]. Peptides were palmitified before entrapment into
ISCOMs using the reagent N-Palmitoyloxy succinimide
[16]. ISCOMs containing peptide antigens were pelleted
by centrifugation on sucrose gradient. The amount of pep-
tide incorporated in the ISCOMs was estimated using
colorimetric assay [17]. The efficiency of incorporation
was found to be 40–50%.
Transmission electron microscopy (TEM) studies
The size, shape and morphology of the preparations were
studied by TEM studies.
Immunizations
V3-gp41, gp41, p17 and p24 peptide(s) alone adsorbed
on alum or incorporated in liposomes (with or without
adjuvant MA729) or in ISCOMs were used as immuno-
gens. Each peptide was studied in all the four groups.
Dose of 25 µg of peptide adsorbed on alum and 5 µg in
liposomes was standardized to study the humoral
response in all the four haplotypes. For every dose, four
mice were used in a group for every haplotype studied.
Whenever MA729 was included in the formulation, the
amount of adjuvant i.e. 50 µg (optimal dose) was kept
constant with 5 µg of all the peptide formulations. Mice
were immunized in the footpad on days 0, 21, 35 and 42.
Bleeds were collected on days 27(Ist), 42(IInd) and 60th
(IIIrd). The third bleed was taken without a booster dose.
Amounts of individual peptides in cocktail mixture fol-
lowed identical immunization schedule as described
above.
Estimation of total anti-peptide antibodies by EIA
Peptide specific antibodies were detected at fixed antisera
dilution (1:100) as well as by measuring the peak (end
point) titers. The peak titers were expressed and assessed
as the reciprocal of sera dilution which gave an absorb-
ance > 0.2 (i.e. ± 4 standard deviations from the mean val-
ues of pre immune sera).
Estimation of IgG isotypes
IgG subclasses were determined using the isotyping kit.
Plates were coated overnight with 100 ng/well of peptides.
Usual ELISA procedure was followed using goat anti-
mouse IgG subclass monoclonal antibodies (Sigma iso-
typing kit) at 1:1000 dilutions for IgG1, IgG2a, IgG2b or
IgG3. The respective peptide mice antiserum was used at
1:100 dilutions. Pre-immune sera were used as negative
control.
Measurement of true affinity (KD) by EIA
The binding affinity of antibodies of different antigenic
formulations were determined by measuring the KD (dis-
sociation constant) value using the reported protocol [18]
in high and low responder strains of mice. Peptide antigen
at various molar concentrations (1 × 10-7 M to 1 × 10-10 M)
was incubated at a fixed dilution 1:500 of the respective
peptide-antiserum. The unbound antibodies were then
determined using an indirect ELISA. Scatchard and Klotz
mathematical equation was used to calculate the KD value.
AO / (AO-A) = 1 + KD / aO, AO = Absorbance without anti-
gen, A = Absorbance with free antigen. aO= Free antigen
concentration. The equation permits the determination of
dissociation constant even if specific antibody concentra-
tion is not known. The equation is of a straight line and
the slope determines the KD value.
HIV microplaque assay
Human immunodeficiency virus (HIV) plaque assay was
done with CD4+ expressing MT-2 cell line as described
[19]. This assay permits or works with anti-envelope anti-
bodies and not with the core protein (p17 and p24) anti-
bodies. All sera were heat inactivated before use. Virus and
sera to be tested were diluted in 50% assay medium (85 %
DMEM with 15% fetal bovine serum, 2 µg of polybrene)
and 50% normal human plasma pools (NHPP). MT-2
cells were added to each well and incubated for seven days
at 37°C in 5% CO2 and stained with propidium iodide.
Representative peptide antisera that showed peak titers in
a given haplotype with a given formulation were used for
the HIV microplaque assay. The neutralizing titer of each
serum sample was expressed as the inverse of the greatest
dilution of serum, which resulted in 50% inhibition in the
average plaque count relative to the count in the control
wells. The percent inhibition at each dilution was calcu-
lated using the mathematical equation was expressed as
percent control.
HIV-1 Biotinylated Liquid Phase Peptide ELISA
Peptide binding assays was done to check the crossreactiv-
ity of antiserum with different Clades or isolates of HIV.
ELISA plates were coated with avidin subsequently
blocked and then was incubated with 50 ng/well bioti-
nylated peptides. Four fold-diluted antiserum was used
from 1:100 to 1:6000. Titer of the antisera was defined as
reciprocal of the dilution, which gave a mean absorbance
of 0.5.
Antigen induced T-cell proliferation assay
To study the antigen induced T cell stimulation and to
optimize the day of maximal T cell response V3-gp41 pep-
tide adsorbed on alum was used to immunize mice of
haplotype H-2d. 25 µg of peptide adsorbed on alum was
immunized on day 0, boosted with half of the primary
dose on 8th day and mice were sacrificed separately on 12th
and 15th day. Separate groups of mice also received a
Percent inhibition (control):
Mean plaques per well in serum m dilution
Mean plaques per well without serum
× 100Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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booster on 12th day followed by sacrifice on 15th and 20th
day.
V3-gp41, gp41, p17 and p24 peptides were separately
adsorbed on alum and immunized in four different mice
of haplotypes H-2d, H-2b, H-2k and H-2q with 25 µg of
peptide dose in primary immunization and 12.5 µg for
subsequent boosters. A cocktail peptide approach was
also studied in a high responder H-2b and a low responder
H-2k with 25 µg of peptide equivalent immunized in
alum, with half the primary dose for booster
immunization.
Proliferation Assay and assay procedure
Mice spleen cells obtained after immunization with
respective peptides in alum were in vitro stimulated with
peptide alone or peptide entrapped in liposomes (with or
without MA729) or peptide entrapped in ISCOMs as stud-
ied for four different strains. In another set of experiment
V3-gp41 peptide was immunized along with MA729 and
the spleen cells obtained were in vitro stimulated with
peptide alone, peptide entrapped in liposomes (with or
without MA729) or in ISCOMs. Moreover to look for the
mitogenic activity of MA729, mice were primed with the
adjuvant and the spleen cells were in vitro stimulated with
MA729 (alone or in liposomes) and with V3-gp41 peptide
alone or entrapped along with MA729 in liposomes. T cell
proliferation was also studied using cocktail mixture of
peptides adsorbed in alum and in vitro stimulated with
respective peptides alone or entrapped in liposomes (with
or without MA729) or in ISCOMs. Cells were cultured in
triplicate and Conconavalin A 5 µg/ml was used as a pos-
itive control. Negative control consisted of unstimulated
cells containing the media alone. Cells were cultured for
72h in a humidified chamber with at 37°C, 5% CO2. 50
µl culture supernatants were collected for estimation of IL-
2, IL-4 & IFN-γ. The cells in each well were pulsed with 0.5
µCi of 3H (6.7 Ci/m mole) and incubated for 18 hrs. Thy-
midine incorporation was measured in a liquid scintilla-
tion counter (Wallac B-counter, counting efficiency 65%).
Stimulation index was calculated as:
Measurement of Cytokines
The culture supernatants collected during antigen induced
T-cell proliferation assay were used to measure cytokine
levels (IL-2, IL-4 & IFN-γ). Culture supernatants were
taken from wells pulsed with the optimal antigen concen-
tration, which showed the maximal stimulation index, as
assayed for different peptides. The culture supernatants
obtained were centrifuged at 5,000 rpm for 20 min and
filtered through 0.22 µM Millipore membranes and were
quantitated using duo set ELISA kits (Genzyme Corp.,
USA) as per the manufacturer's instructions.
Measurement of cytokines using cocktail approach
Cytokines IFN-γ, IL-2 and IL-4 were measured in the cul-
ture supernatants obtained after priming with cocktail
mixture in alum and in vitro stimulation with respective
peptides alone or entrapped in liposomes (with or with-
out MA729) or in ISCOMs.
Statistical analysis
Levels of statistical significance (P) values for the differ-
ence in total IgG (in the sera raised against different anti-
gen preparations) were performed by Non-Parametric
Kruskal-Walli's one-way analysis of variance. For calculat-
ing the P value in respect of difference in isotypes, Non-
Parametric Friedman's two way ANOVA with multiple
range tests between the different formulations and
Kruskal-Walli's one-way ANOVA between different IgG
subclasses were applied. Levels of statistical significance
between antibody levels in the first, second, third and
fourth (bleeds except otherwise stated) were determined
by Wilcoxson's signed rank test. The difference between
the T cell proliferation and cytokine levels of peptide
alone, peptide in liposomes (with or without adjuvant)
and in ISCOMs were also analyzed using Non-Parametric
Kruskal-Walli's one way analysis of variance by ranks.
Results
TEM Studies
TEM studies revealed that the size of the ISCOMs and
liposomes to be in the range of 40 nm and 300 nm respec-
tively in diameter.
Optimization of antigen dose in different adjuvant 
formulation
The amount of peptide antigen required to produce opti-
mum immune response was standardized using V3-gp41
peptide and was found to be 25 µg, for first immunization
and 12.5 µg for subsequent boosters for peptide adsorbed
on alum (data not shown). For liposome and ISCOM
preparations, the optimum dose that showed peak anti-
body levels was found to be 5 µg. Adjuvant combination
of 5:50 µg dose of peptide: MA729 elicited highest anti-
body response, in a dose kinetic study. The above doses
were fixed for subsequent immunizations with other pep-
tide antigens in different haplotypes.
Humoral response (Total IgG)
Sera obtained from of mice of different genetic back-
ground with synthetic peptides in different formulations
were assayed for peptide specific antibodies. The results
show that all the peptides in alum were immunogenic in
one or more of the strains of mice depending upon the
nature of the formulation used. V3-gp41 and
SI
mean cpm of cells stimulated with antigen
    
:
mean cpm of con ntrol wells  Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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gp41peptides produced high titer antibodies and the peak
titers sustained even in third bleed without booster
immunization while the antibody titers for p17 and p24
peptides were moderate in all the strains (Fig.
1A,1B,1C,1D,1E,1F,1G,1H,1I,1J,1K,1L,1M,1N,1O,1P).
Highest sustained antibody titers (>60 days) were
observed in all the strains with peptide entrapped along-
with MA729 in liposomes and were statistically significant
(P < 0.05) as compared to the other formulations.
For V3-gp41 peptide, the antibody titres obtained for mice
bearing the haplotype H2b and H2d were higher as com-
pared to mice bearing the haplotype H-2k and H-2q. Pep-
tide: MA729 in liposomes showed the highest antibody
titres in all haplotypes studied (Fig. 1A,1B,1C,1D). It is
interesting to note that the peptide itself showed compa-
rable peak titres of 1/102,400 in both liposome and
ISCOM preparation except in secondary bleed of mice
bearing the haplotype H-2 d&k  with peak titers of 1/
64,000. Secondary immune response for V3-gp41 peptide
in liposomes (with or without adjuvant) generated similar
peak titer of 1/128,000 in mice bearing the haplotypes H-
2b. Comparable peak titers were observed for V3-
gp41peptide entrapped in liposomes and ISCOMs except
in the third bleed of mice bearing the haplotype H-2d&k.
The antibody response in liposomes was 2–4 folds higher
than the ISCOM based preparation. Although, liposome
and ISCOM preparations showed slight strain-to-strain
Kinetics of antibody response and estimation of end point titers of murine antisera raised during course of immunization in dif- ferent formulations for V3-gp41 (A-D), gp41 (E-H), p17(I-L) and p24(M-P) Figure 1
Kinetics of antibody response and estimation of end point titers of murine antisera raised during course of immunization in dif-
ferent formulations for V3-gp41 (A-D), gp41 (E-H), p17(I-L) and p24(M-P). HIV-1 peptides. Mice were immunized as described 
in Materials and Methods in different antigenic formulations. The serum antibody titers were determined by ELISA. Titers were 
assessed as the highest sera dilution giving an absorbance of > 0.3.
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variation in antibody titers, the difference however was
statistically insignificant.
Peak antibody response with gp41 peptide was signifi-
cantly higher (p < 0.01) in mice bearing the haplotype H-
2d&k as compared to haplotype H-2b&q irrespective of the
nature of the formulation used (Fig 1E,1F,1G,1H). The
antibody response in liposome preparation for gp41 pep-
tide together with adjuvant was highly significant (P <
0.01) with peak titers of 1/102,400 for all the haplotypes
especially in the third bleed, when compared to alum
preparation with peak titers of 1/32,000. The titers were
significantly higher in liposomes and ISCOM preparation
for all the haplotypes and in all the bleeds as compared to
alum based formulation. Although all the haplotypes
responded equally well, mice bearing haplotypes H-2b
and H-2k showed the highest and lowest antibody titers
respectively among the four haplotypes studied.
P17 and p24 peptide in alum showed peak titers of 1/
6,400 and 1/3,200 respectively (Fig.
1I,1J,1K,1L,1M,1N,1O,1P). All the p17 peptide formula-
tions were immunogenic, but mice bearing the haplotype
H-2q showed maximum peak titers of 1/51,200 followed
by haplotypes H-2k (1/32,000), H-2b and H-2d(1/16,000)
(Fig 1I,1J,1K,1L). High antibody titers were obtained
when the p17 antigen was entrapped in liposomes (1/
32,000) or ISCOMs (1/51,200). Addition of adjuvant
MA729, improved the immunogenicity of the formula-
tions with antibody levels statistically significant (P <
0.01) for p17 peptide in all the haplotypes. For p24 pep-
tide, mice bearing the haplotypes H-2k,b&d showed peak
titers of 1/25,600 in liposomes containing adjuvant, but
mice bearing the haplotype H-2q failed to show similar
response (Fig 1M,1N,1O,1P). Unlike V3-gp41 and gp41
peptide, the antibody response for p17 and p24 peptide
was significantly lower and the pattern of antibody
response obtained for different delivery systems was more
or less same. Peptide (5 µg) in liposome (with or without
adjuvant) and ISCOMs elicited antibody response, which
was 3–4 fold higher in magnitude as compared to alum,
based preparations.
Humoral response to cocktail peptides
Humoral response to mixture of peptides containing
equivalent of V3-gp41, gp41, p17 and p24 in different for-
mulations were studied in high (H-2d) and low responder
strain (H-2k) of mice (Fig. 2A,2B,2C,2D). When peptide
specific antibodies were measured, delivery in alum
showed lower antibody response as compared to other
adjuvant formulations. For V3-gp41 peptide booster
response was observed for all the formulations and was
maintained till third bleed (Fig. 2A). gp41 peptide in lipo-
some (with or without adjuvant) or in ISCOMs did not
induce significant boosting effect in both the haplotypes
however the levels of antibodies were maintained for all
the formulations till the third bleed (Fig. 2B). p17 peptide
showed booster response for both liposomes (with or
without MA729) and ISCOMs formulations in both the
haplotypes studied (Fig. 2C). Irrespective of the strain and
the formulation, V3-gp41 specific antibodies were found
to be predominant followed by p17, gp41 and p24 anti-
peptide antibodies.
Very low levels of anti p24 antibodies were observed for
all the formulations in both the haplotypes. The levels of
antibody for peptide entrapped in liposomes (with or
without adjuvant) and in ISCOMs were statistically signif-
icant (P < 0.05) as compared to antibody response in
alum formation.
IgG subclass estimation
Mice immunized with peptide or peptide formulations
predominantly generated IgG2a/IgG2b isotypes and the
levels were comparable in all the bleeds and strains. The
inclusion of adjuvant in liposomes formulation showed
higher levels of IgG2a/2b subclass when compared to
other formulations (Table 1).
Mice bearing the haplotype H-2d and H-2q induced higher
levels of IgG2a and IgG2b isotypes compared to H-2b and
H-2k (Table 1) irrespective of the nature of the peptide or
formulations used which was statistically significant (p <
0.01) in both primary and secondary bleeds. Mice bearing
the haplotype H-2d showed specific IgG2a and IgG2b iso-
type response for all the preparations, which was statisti-
cally significant (P < 0.01) in both primary and secondary
bleeds. The primary, secondary and tertiary bleed showed
high levels of IgG2b for V3-gp41 and gp41 peptide in
liposomes (with or without adjuvant) for the haplotype
H-2q. Both IgG2a and IgG2b isotypes were detected in
both alum and ISCOM preparations in all the haplotypes.
Mice bearing the haplotype H-2q induced maximal levels
of IgG2a and IgG2b antibodies for all the V3-gp41 peptide
formulations in all the bleeds, which was statistically sig-
nificant (P < 0.01) when compared with isotypes IgG1
and IgG3. P17 and p24 peptides too generated signifi-
cantly high levels of IgG2a/2b isotypes both in liposomes
(p < 0.01) and ISCOMs (P < 0.05) preparation in all the
haplotypes. The levels of IgG2b isotype were significant (P
< 0.05) as compared to IgG1 or IgG3 whereas the levels of
IgG2a were more or less comparable with IgG2b for the
liposome preparation in all the haplotypes except for
mice bearing the haplotype H-2b strain. There was a signif-
icant increase in both the isotype levels (IgG2a/2b) in
booster immunization for both the peptides. For p24 pep-
tide, mice bearing the haplotype H-2k strain produced
maximal levels of IgG2a and IgG2b than the mice of other
haplotypes.Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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Measurement of KD by ELISA
The relative affinity (KD) of the antibodies raised against
different preparations was assayed by measuring the dis-
sociation constant(KD values) in high and low responder
strain. (Table 2).
All the peptides generated high affinity antibodies in both
the strains irrespective of the nature of the formulation
used. Peptides entrapped in liposomes (with or without
adjuvant) invariably generated high affinity antibodies as
compared to alum and ISCOM preparations. The alum
adsorbed preparations for V3-gp41 peptide elicited high
affinity antibodies (KD-0.20 nM). The KD value observed
for other peptides was in the range of (0.9 nM–24.5 nM).
The KD values for liposome preparations were four to five
folds lower viz. (0.10 nM–1.5 nM) as compared to the
alum based preparations for V3-gp41, gp41 and p17 pep-
tide when tested in both high and low responder strains.
Five-fold increase in affinity was observed for p24 peptide
liposome preparation when compared to alum formula-
tion of other peptides. Addition of adjuvant further
increased the affinity by 5–10 folds (0.05 nM–1.40 nM)
depending on the nature of the formulations used for all
the peptides tested. In general, V3-gp41 peptide had a
lower KD (0.1 nM – 0.9 nM) as compared to KD values
observed for other peptides was significantly high which
was in the range of 3.5 nM – 24.5 nM.
MT-2 Microplaque Assay
The MT-2 Cell line used was an HTLV-1 transformed
human T-cell line generated from co-cultivation of cord
blood lymphocytes and leukemic cells from a patient,
which produces viral particles. MT-2 cells demonstrate a
characteristic cytopathic response, which facilitates the
Estimation of V3-gp41 (A), gp41 (B), p17 (C) and p24 (D) peptide specific antibodies generated by immunizing the mice with  cocktail of HIV peptides Figure 2
Estimation of V3-gp41 (A), gp41 (B), p17 (C) and p24 (D) peptide specific antibodies generated by immunizing the mice with 
cocktail of HIV peptides. Peptide-specific antibody levels were determined by ELISA at fixed antibody dilution (1:100).
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Table 1: IgG isotypes for mice of different haplotypes (H-2b, H-2k, H-2q, H-2d). Estimation of IgG isotypes for different peptide 
formulations in mice bearing haplotypes H-2b(1A), H-2k(1B), H-2q(1C), H-2d(1D). Levels of IgG1, IgG2a, IgG2b and IgG3 and 
determined as described in Materials and Methods at fixed antisera dilution (1:100). IgG2a,2b,2c and IgG3 were determined using ELISA 
in all the three bleeds for all the four peptides in different antigenic formulations using the isotyping kit. The O.D. values represent mean 
± SEM of sixteen mice (four for each haplotype) as studied for the bleeds obtained on 27th (I), 42nd(II), and 60th (III) day.
Table 1A (H-2b)
Formulation Peptide in Alum Peptide in Liposomes Peptide with MA729 in Liposomes Peptide in ISCOMs
Isotype↓ 
Bleed→
I II III I II III I II III I II III
V3-gp41 Peptide
IgG1 0.58 ± 
0.10
0.56 ± 
0.02
0.36 ± 
0.05
0.18 ± 
0.02
0.32 ± 
0.05
0.43 ± 
0.10
0.32 ± 
0.06
0.58 ± 
0.10
0.30 ± 
0.12
0.32 ± 
0.10
0.45 ± 
0.17
0.29 ± 
0.10
IgG2a 0.67 ± 
0.16
0.76 ± 
0.10
0.45 ± 
0.02
0.56 ± 
0.07
0.65 ± 
0.14
0.50 ± 
0.10
0.54 ± 
0.12
0.78 ± 
0.20
0.73 ± 
0.21
0.95 ± 
0.30
1.24 ± 
0.26
1.10 ± 
0.31
IgG2b 0.78 ± 
0.10
0.74 ± 
0.25
0.67 ± 
0.10
0.98 ± 
0.22
1.20 ± 
0.42
1.49 ± 
0.36
1.35 ± 
0.33
1.34 ± 
0.21
1.50 ± 
0.18
1.54 ± 
0.09
1.23 ± 
0.39
1.43 ± 
0.32
IgG3 0.43 ± 
0.17
0.32 ± 
0.12
0.37 ± 
0.04
0.54 ± 
0.10
0.43 ± 
0.08
0.40 ± 
0.05
0.60 ± 
0.10
0.70 ± 
0.10
0.45 ± 
0.06
0.60 ± 
0.10
0.58 ± 
0.03
0.43 ± 
0.05
gp41 Peptide
IgG1 0.10 ± 
0.01
0.12 ± 
0.01
0.10 ± 
0.03
0.10 ± 
0.04
0.42 ± 
0.05
1.16 ± 
0.10
0.10 ± 
0.03
0.27 ± 
0.02
0.30 ± 
0.06
0.10 ± 
0.01
0.14 ± 
0.02
0.10 ± 
0.01
IgG2a 0.13 ± 
0.02
0.21 ± 
0.02
0.11 ± 
0.01
0.10 ± 
0.01
0.52 ± 
0.03
0.18 ± 
0.02
0.10 ± 
0.01
0.60 ± 
0.10
0.40 ± 
0.12
0.10 ± 
0.01
0.20 ± 
0.01
0.10 ± 
0.02
IgG2b 0.31 ± 
0.01
0.32 ± 
0.13
0.23 ± 
0.01
1.20 ± 
0.23
1.29 ± 
0.32
0.10 ± 
0.01
1.12 ± 
0.32
1.34 ± 
0.02
1.31 ± 
0.12
0.58 ± 
0.10
1.46 ± 
0.23
0.78 ± 
0.32
IgG3 0.13 ± 
0.03
0.13 ± 
0.02
0.14 ± 
0.01
0.09 ± 
0.01
0.18 ± 
0.01
0.21 ± 
0.02
0.41 ± 
0.03
0.28 ± 
0.01
0.58 ± 
0.10
0.08 ± 
0.01
0.32 ± 
0.03
0.2 ± 0.04
p17 Peptide
IgG1 0.58 ± 
0.10
0.64 ± 
0.24
0.65 ± 
0.03
0.72 ± 
0.18
0.70 ± 
0.17
0.84 ± 
0.34
0.64 ± 
0.28
0.79 ± 
0.03
0.63 ± 
0.16
0.69 ± 
0.18
0.60 ± 
0.10
0.70 ± 
01.8
IgG2a 0.85 ± 
0.20
0.89 ± 
0.32
0.90 ± 
0.09
0.80 ± 
0.02
1.01 ± 
0.04
0.83 ± 
0.34
0.85 ± 
0.32
1.07 ± 
0.22
0.81 ± 
0.31
0.70 ± 
0.18
1.01 ± 
0.15
0.77 ± 
0.24
IgG2b 0.61 ± 
0.21
0.79 ± 
0.17
0.61 ± 
0.09
0.71 ± 
0.14
1.16 ± 
0.12
1.28 ± 
0.16
0.71 ± 
0.09
1.18 ± 
0.02
1.31 ± 
0.23
0.61 ± 
0.03
0.87 ± 
0.21
1.29 ± 
0.23
IgG3 0.46 ± 
0.15
0.45 ± 
0.14
0.35 ± 
0.12
0.40 ± 
0.20
0.52 ± 
0.21
0.59 ± 
0.15
0.40 ± 
0.12
0.48 ± 
0.08
0.51 ± 
0.01
0.59 ± 
0.32
0.52 ± 
0.10
0.50 ± 
0.13
p24 Peptide
IgG1 0.34 ± 
0.01
0.30 ± 
0.08
0.35 ± 
0.02
0.70 ± 
0.16
0.42 ± 
0.12
0.53 ± 
0.14
0.49 ± 
0.12
0.27 ± 
0.03
0.47 ± 
0.05
0.89 ± 
0.05
0.32 ± 
0.04
0.48 ± 
0.15
IgG2a 0.59 ± 
0.13
0.46 ± 
0.15
0.48 ± 
0.14
0.73 ± 
0.15
0.93 ± 
0.23
0.90 ± 
0.32
0.76 ± 
0.23
1.06 ± 
0.40
0.80 ± 
0.20
0.60 ± 
0.13
0.94 ± 
0.16
0.88 ± 
0.15
IgG2b 0.46 ± 
0.17
0.72 ± 
0.08
0.89 ± 
0.23
0.40 ± 
0.02
0.90 ± 
0.04
0.91 ± 
0.09
0.56 ± 
0.17
0.90 ± 
0.23
1.07 ± 
0.32
0.80 ± 
0.10
0.96 ± 
0.16
1.02 ± 
0.32
IgG3 0.58 ± 
0.19
0.40 ± 
0.08
0.42 ± 
0.05
0.36 ± 
0.02
0.32 ± 
0.05
0.35 ± 
0.05
0.52 ± 
0.09
0.40 ± 
0.13
0.35 ± 
0.09
0.53 ± 
0.04
0.37 ± 
0.10
0.34 ± 
0.12
Table 1B (H-2k)
Formulation Peptide in Alum Peptide in Liposomes Peptide with MA729 in Liposomes Peptide in ISCOMs
Isotype ↓ 
Bleed →
I II III I II III I II III I II III
V3-gp41 Peptide
IgG1 0.46 ± 
0.02
0.28 ± 
0.03
0.42 ± 
0.13
0.10 ± 
0.04
0.60 ± 
0.10
0.63 ± 
0.20
0.47 ± 
0.15
0.62 ± 
0.12
0.38 ± 
0.09
0.26 ± 
0.07
0.78 ± 
0.12
0.67 ± 
0.20
IgG2a 0.91 ± 
0.23
0.46 ± 
0.09
0.27 ± 
0.07
0.93 ± 
0.21
0.90 ± 
0.32
0.40 ± 
0.09
0.50 ± 
0.07
0.83 ± 
0.03
0.70 ± 
0.04
0.54 ± 
0.14
0.80 ± 
0.15
0.84 ± 
0.16
IgG2b 0.73 ± 
0.18
0.62 ± 
0.19
0.90 ± 
0.29
1.32 ± 
0.30
1.24 ± 
0.34
1.08 ± 
0.32
0.70 ± 
0.10
1.07 ± 
0.20
1.35 ± 
0.27
0.70 ± 
0.17
0.80 ± 
0.19
0.95 ± 
0.16Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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IgG3 0.26 ± 
0.02
0.17 ± 
0.03
0.61 ± 
0.04
0.26 ± 
0.09
0.31 ± 
0.10
0.29 ± 
0.04
0.16 ± 
0.03
0.37 ± 
0.04
0.18 ± 
0.08
0.24 ± 
0.08
0.16 ± 
0.02
0.26 ± 
0.02
gp41 Peptide
IgG1 0.10 ± 
0.03
0.11 ± 
0.04
0.20 ± 
0.05
0.73 ± 
0.16
1.04 ± 
0.24
0.70 ± 
0.26
0.40 ± 
0.06
1.27 ± 
0.43
1.28 ± 
0.35
0.60 ± 
0.02
0.30 ± 
0.02
0.06 ± 
0.01
IgG2a 0.12 ± 
0.01
0.24 ± 
0.10
0.20 ± 
0.04
0.63 ± 
0.09
1.27 ± 
0.26
1.02 ± 
0.29
0.47 ± 
0.19
1.35 ± 
0.09
1.41 ± 
0.12
0.69 ± 
0.16
0.79 ± 
0.11
0.60 ± 
0.10
IgG2b 0.25 ± 
0.08
0.26 ± 
0.09
0.27 ± 
0.07
0.94 ± 
0.20
1.31 ± 
0.30
1.23 ± 
0.19
1.32 ± 
0.20
1.37 ± 
0.41
1.39 ± 
0.32
0.97 ± 
0.10
1.14 ± 
0.19
1.24 ± 
0.16
IgG3 0.17 ± 
0.20
0.07 ± 
0.16
0.10 ± 
0.03
0.70 ± 
0.09
0.47 ± 
0.07
0.30 ± 
0.03
0.37 ± 
0.03
0.47 ± 
0.22
0.58 ± 
0.06
0.40 ± 
0.03
0.31 ± 
0.01
0.25 ± 
0.08
p17 Peptide
IgG1 0.45 ± 
0.10
0.53 ± 
0.03
0.50 ± 
0.14
0.60 ± 
0.17
0.67 ± 
0.19
0.70 ± 
0.03
0.53 ± 
0.12
0.60 ± 
0.18
0.50 ± 
0.11
0.51 ± 
0.10
0.61 ± 
0.14
0.59 ± 
0.09
IgG2a 0.44 ± 
0.03
0.79 ± 
0.13
0.60 ± 
0.16
0.60 ± 
0.08
0.82 ± 
0.23
0.68 ± 
0.11
0.50 ± 
0.10
0.83 ± 
0.07
0.67 ± 
0.01
0.50 ± 
0.02
0.63 ± 
0.17
0.60 ± 
0.02
IgG2b 0.38 ± 
0.02
0.65 ± 
0.16
0.53 ± 
0.03
0.48 ± 
0.02
1.09 ± 
0.19
1.05 ± 
0.18
0.45 ± 
0.10
1.05 ± 
0.28
1.07 ± 
0.21
0.46 ± 
0.31
0.72 ± 
0.26
1.07 ± 
0.20
IgG3 0.24 ± 
0.09
0.32 ± 
0.06
0.21 ± 
0.02
0.35 ± 
0.08
0.43 ± 
0.10
0.45 ± 
0.07
0.20 ± 
0.01
0.36 ± 
0.08
0.38 ± 
0.03
0.30 ± 
0.02
0.33 ± 
0.06
0.35 ± 
0.02
p24 Peptide
IgG1 0.28 ± 
0.03
0.38 ± 
0.07
0.31 ± 
0.03
0.40 ± 
0.10
0.59 ± 
0.04
0.51 ± 
0.16
0.40 ± 
0.18
0.50 ± 
0.15
0.42 ± 
0.12
0.40 ± 
0.12
0.60 ± 
0.23
0.42 ± 
0.23
IgG2a 0.52 ± 
0.21
0.66 ± 
0.22
0.69 ± 
0.11
0.60 ± 
0.09
0.70 ± 
0.09
0.62 ± 
0.16
0.40 ± 
0.06
0.76 ± 
0.03
0.78 ± 
0.14
0.80 ± 
0.10
0.77 ± 
0.21
0.48 ± 
0.08
IgG2b 0.51 ± 
0.07
0.54 ± 
0.03
0.58 ± 
0.09
0.70 ± 
0.16
0.81 ± 
0.03
0.90 ± 
0.31
0.70 ± 
0.26
0.92 ± 
0.21
0.60 ± 
0.22
0.80 ± 
0.21
0.97 ± 
0.17
0.45 ± 
0.05
IgG3 0.34 ± 
0.10
0.32 ± 
0.09
0.31 ± 
0.01
0.36 ± 
0.10
0.88 ± 
0.07
0.64 ± 
0.21
0.48 ± 
0.01
0.52 ± 
0.09
0.69 ± 
0.16
0.60 ± 
0.20
0.72 ± 
0.19
0.44 ± 
0.09
Table 1C (H-2q)
Formulation Peptide in Alum Peptide in Liposomes Peptide with MA729 in Liposomes Peptide in ISCOMs
Isotype↓ 
Bleed →
I II III I II III I II III I II III
V3-gp41 peptide
IgG1 0.18 ± 
0.07
0.14 ± 
0.02
0.17 ± 
0.03
0.14 ± 
0.01
0.10 ± 
0.01
0.36 ± 
0.06
0.13 ± 
0.02
0.32 ± 
0.12
0.33 ± 
0.03
0.51 ± 
0.02
0.63 ± 
0.11
0.70 ± 
0.09
IgG2a 0.26 ± 
0.06
0.45 ± 
0.05
0.56 ± 
0.07
0.70 ± 
0.02
0.77 ± 
0.01
0.89 ± 
0.10
0.95 ± 
0.21
0.93 ± 
0.12
0.90 ± 
0.10
1.23 ± 
0.09
1.16 ± 
0.02
1.31 ± 
0.20
IgG2b 0.64 ± 
0.05
0.56 ± 
0.06
0.38 ± 
0.07
0.90 ± 
0.21
0.95 ± 
0.09
1.30 ± 
0.16
0.94 ± 
0.14
0.96 ± 
0.23
1.31 ± 
0.33
1.24 ± 
0.20
1.34 ± 
0.14
1.10 ± 
0.27
IgG3 0.12 ± 
0.02
0.10 ± 
0.01
0.19 ± 
0.03
0.11 ± 
0.01
0.17 ± 
0.04
0.23 ± 
0.03
0.15 ± 
0.06
0.26 ± 
0.17
0.34 ± 
0.08
0.10 ± 
0.02
0.20 ± 
0.01
0.70 ± 
0.03
gp41 Peptide
IgG1 0.24 ± 
0.01
0.23 ± 
0.04
0.06 ± 
0.01
0.41 ± 
0.09
0.42 ± 
0.06
0.32 ± 
0.02
0.34 ± 
0.10
0.40 ± 
0.16
0.36 ± 
0.10
0.30 ± 
0.03
0.31 ± 
0.10
0.24 ± 
0.05
IgG2a 0.52 ± 
0.04
0.57 ± 
0.05
0.60 ± 
0.05
0.65 ± 
0.04
0.77 ± 
0.07
0.89 ± 
0.08
0.60 ± 
0.10
1.28 ± 
0.09
0.95 ± 
0.18
0.84 ± 
0.21
0.73 ± 
0.30
0.65 ± 
0.17
IgG2b 0.67 ± 
0.31
0.72 ± 
0.08
0.25 ± 
0.02
1.40 ± 
0.15
1.35 ± 
0.19
1.01 ± 
0.21
1.14 ± 
0.22
1.09 ± 
0.34
1.46 ± 
0.52
0.91 ± 
0.19
0.82 ± 
0.21
0.72 ± 
0.08
IgG3 0.18 ± 
0.06
0.28 ± 
0.03
0.23 ± 
0.02
0.51 ± 
0.03
0.51 ± 
0.06
0.30 ± 
0.01
0.28 ± 
0.06
0.28 ± 
0.07
0.53 ± 
0.17
0.29 ± 
0.03
0.32 ± 
0.16
0.46 ± 
0.20
p17 Peptide
Table 1: IgG isotypes for mice of different haplotypes (H-2b, H-2k, H-2q, H-2d). Estimation of IgG isotypes for different peptide 
formulations in mice bearing haplotypes H-2b(1A), H-2k(1B), H-2q(1C), H-2d(1D). Levels of IgG1, IgG2a, IgG2b and IgG3 and 
determined as described in Materials and Methods at fixed antisera dilution (1:100). IgG2a,2b,2c and IgG3 were determined using ELISA 
in all the three bleeds for all the four peptides in different antigenic formulations using the isotyping kit. The O.D. values represent mean 
± SEM of sixteen mice (four for each haplotype) as studied for the bleeds obtained on 27th (I), 42nd(II), and 60th (III) day. (Continued)Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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IgG1 0.34 ± 
0.08
0.32 ± 
0.02
0.24 ± 
0.17
0.76 ± 
0.16
0.30 ± 
0.07
0.34 ± 
0.01
0.38 ± 
0.02
0.26 ± 
0.01
0.30 ± 
0.06
0.39 ± 
0.09
0.29 ± 
0.02
0.28 ± 
0.01
IgG2a 0.51 ± 
0.01
0.36 ± 
0.04
0.38 ± 
0.06
0.72 ± 
0.02
0.90 ± 
012
0.88 ± 
0.21
0.74 ± 
0.15
0.92 ± 
0.10
0.89 ± 
0.19
0.56 ± 
0.12
1.03 ± 
0.02
0.86 ± 
0.20
IgG2b 0.46 ± 
0.02
0.71 ± 
0.08
0.88 ± 
0.09
0.50 ± 
0.23
0.95 ± 
0.32
0.91 ± 
0.30
0.55 ± 
0.23
0.92 ± 
0.32
0.94 ± 
0.28
0.52 ± 
0.09
0.99 ± 
0.21
1.05 ± 
0.21
IgG3 0.56 ± 
0.01
0.42 ± 
0.14
0.40 ± 
0.15
0.56 ± 
0.08
0.32 ± 
0.02
0.36 ± 
0.05
0.32 ± 
0.07
0.27 ± 
0.08
0.35 ± 
0.05
0.34 ± 
0.12
0.40 ± 
0.11
0.34 ± 
0.10
p24 Peptide
IgG1 0.40 ± 
0.05
0.44 ± 
0.08
0.38 ± 
0.02
0.30 ± 
0.03
0.70 ± 
0.10
0.60 ± 
0.11
0.61 ± 
0.08
0.32 ± 
0.03
0.42 ± 
0.06
0.29 ± 
0.06
0.76 ± 
0.13
0.50 ± 
0.02
IgG2a 0.54 ± 
0.11
0.62 ± 
0.21
0.61 ± 
0.06
0.76 ± 
0.03
0.88 ± 
0.05
1.04 ± 
0.18
0.67 ± 
0.02
1.07 ± 
0.18
1.09 ± 
0.21
0.63 ± 
0.21
1.00 ± 
0.20
1.10 ± 
0.17
IgG2b 0.36 ± 
0.08
0.32 ± 
0.04
0.55 ± 
0.04
0.69 ± 
0.14
1.08 ± 
0.16
0.90 ± 
0.19
0.72 ± 
0.07
1.18 ± 
0.13
1.16 ± 
0.22
1.60 ± 
0.07
1.19 ± 
0.03
0.90 ± 
0.09
IgG3 0.31 ± 
0.03
0.57 ± 
0.07
0.38 ± 
0.03
0.46 ± 
0.04
0.49 ± 
0.09
0.50 ± 
0.10
0.31 ± 
0.04
0.48 ± 
0.05
0.42 ± 
0.11
0.52 ± 
0.23
0.54 ± 
0.02
0.32 ± 
0.10
Table 1D (H-2d)
Formulation Peptide in Alum Peptide in Liposomes Peptide with MA729 in Liposomes Peptide in ISCOMs
Isotype↓ 
Bleed →
I II III I II III I II III I II III
V3-gp41 peptide
IgG1 0.33 ± 
0.03
0.27 ± 
0.02
0.42 ± 
0.03
0.65 ± 
0.08
0.52 ± 
0.02
0.47 ± 
0.02
0.30 ± 
0.01
0.10 ± 
0.06
0.10 ± 
0.01
0.21 ± 
0.09
0.28 ± 
0.02
0.45 ± 
0.05
IgG2a 0.49 ± 
0.02
0.59 ± 
0.11
0.91 ± 
0.19
0.69 ± 
0.04
1.03 ± 
0.09
1.93 ± 
0.19
0.46 ± 
0.10
0.70 ± 
0.20
0.38 ± 
0.04
0.54 ± 
0.03
0.40 ± 
0.07
0.80 ± 
0.01
IgG2b 0.97 ± 
0.03
1.81 ± 
0.12
1.70 ± 
0.21
1.10 ± 
0.21
1.74 ± 
0.20
1.47 ± 
0.03
1.70 ± 
0.32
1.32 ± 
0.21
0.90 ± 
0.08
1.76 ± 
0.03
1.24 ± 
0.08
1.80 ± 
0.14
IgG3 0.35 ± 
0.08
0.27 ± 
0.04
0.51 ± 
0.18
0.70 ± 
0.15
0.40 ± 
0.08
0.65 ± 
0.05
0.30 ± 
0.04
0.65 ± 
0.02
0.32 ± 
0.02
0.29 ± 
0.08
0.45 ± 
0.03
0.42 ± 
0.02
gp41 Peptide
IgG1 0.13 ± 
0.03
0.17 ± 
0.02
0.12 ± 
0.03
0.63 ± 
0.06
0.91 ± 
0.05
0.43 ± 
0.13
0.44 ± 
0.04
0.97 ± 
0.23
1.20 ± 
0.21
0.30 ± 
0.20
0.40 ± 
0.01
0.52 ± 
0.10
IgG2a 0.23 ± 
0.10
0.34 ± 
0.07
0.36 ± 
0.09
0.87 ± 
0.03
0.90 ± 
0.05
1.01 ± 
0.09
0.54 ± 
0.15
1.45 ± 
0.19
1.60 ± 
0.28
0.76 ± 
0.17
0.83 ± 
0.18
0.76 ± 
0.13
IgG2b 0.36 ± 
0.12
0.45 ± 
0.01
0.43 ± 
0.06
1.23 ± 
0.02
1.21 ± 
0.01
1.10 ± 
0.04
1.34 ± 
0.09
1.43 ± 
0.03
1.49 ± 
0.43
1.04 ± 
0.09
0.97 ± 
0.12
0.80 ± 
0.21
IgG3 0.17 ± 
0.03
0.07 ± 
0.01
0.10 ± 
0.02
0.34 ± 
0.03
0.57 ± 
0.08
0.74 ± 
0.12
0.54 ± 
0.16
0.67 ± 
0.09
0.60 ± 
010
0.48 ± 
0.02
0.67 ± 
0.13
0.60 ± 
0.03
p17 Peptide
IgG1 0.19 ± 
0.01
0.36 ± 
0.05
0.28 ± 
0.06
0.02 ± 
0.01
0.65 ± 
0.21
0.50 ± 
0.02
1.21 ± 
0.09
0.50 ± 
0.10
0.67 ± 
0.12
0.23 ± 
0.02
0.55 ± 
0.19
0.81 ± 
0.09
IgG2a 0.27 ± 
0.03
0.40 ± 
0.03
0.61 ± 
0.12
0.95 ± 
0.25
0.92 ± 
0.21
0.72 ± 
0.01
0.85 ± 
0.10
0.95 ± 
0.17
0.86 ± 
0.18
0.77 ± 
0.18
0.98 ± 
0.16
0.90 ± 
0.32
IgG2b 0.49 ± 
0.07
0.68 ± 
0.09
0.69 ± 
0.07
0.82 ± 
0.06
0.85 ± 
0.05
0.99 ± 
0.24
0.87 ± 
0.14
0.95 ± 
0.32
0.97 ± 
0.21
0.63 ± 
0.01
1.05 ± 
0.20
1.15 ± 
0.22
Table 1: IgG isotypes for mice of different haplotypes (H-2b, H-2k, H-2q, H-2d). Estimation of IgG isotypes for different peptide 
formulations in mice bearing haplotypes H-2b(1A), H-2k(1B), H-2q(1C), H-2d(1D). Levels of IgG1, IgG2a, IgG2b and IgG3 and 
determined as described in Materials and Methods at fixed antisera dilution (1:100). IgG2a,2b,2c and IgG3 were determined using ELISA 
in all the three bleeds for all the four peptides in different antigenic formulations using the isotyping kit. The O.D. values represent mean 
± SEM of sixteen mice (four for each haplotype) as studied for the bleeds obtained on 27th (I), 42nd(II), and 60th (III) day. (Continued)Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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observation of microplaques. Antiserum to be tested and
Preimmune sera (PIS) were diluted three folds from 1:5 to
1:32805 and HIV MN was co-cultured with MT2 cells.
Syncytia were counted in each of the respective well at dif-
ferent antisera dilutions. The average number of syncytia
observed for each dilution was calculated and was
expressed as percent of control. Neutralization of HIV-
MNH9 strain in MT-2 clone alpha-4 cells by antiserum
raised against V3-gp41, gp41, was observed (Fig. 3). 50%
syncytia were inhibited at an antiserum dilution of 1:15
and 1:33 for gp41 and V3-gp41 peptide respectively
whereas PIS did not showed any non-specific inhibition
(Fig. 3). Greater than 90% of inhibition was observed at a
dilution of 1:6 for V3-gp41 peptide and 1:5 for
gp41peptide.
Peptide Binding Assays
High titer V3-gp41 peptide antisera was tested for the
cross reactivity with various sequences of biotinylated V3
peptides derived from different clades of HIV by direct
binding assays. For p17 and gp41 peptides one represent-
ative biotinylated peptide from HIV MN isolate was used
for studies. Sera raised against V3-gp41 peptide showed
high titers and cross reactivity with V3 peptides derived
from clades A to G, MN, SF2, BR1 and BR2 isolates of HIV
(Table 3). Antibodies raised against p17 and gp41 pep-
tides also reacted with gp41 and p17 peptides derived
from HIV-1 MN isolate thus indicating a spectrum of
immunoreactivity HIV isolates with peptide formulations.
IgG3 0.31 ± 
0.06
0.40 ± 
0.04
0.40 ± 
0.12
0.28 ± 
0.02
0.24 ± 
0.02
0.23 ± 
0.01
0.25 ± 
0.08
0.21 ± 
0.01
0.21 ± 
0.04
0.28 ± 
0.10
0.14 ± 
0.01
0.22 ± 
0.02
p24 Peptide
IgG1 0.24 ± 
0.01
0.41 ± 
0.10
0.43 ± 
0.18
0.20 ± 
0.06
0.68 ± 
0.03
0.57 ± 
0.08
0.24 ± 
0.10
0.61 ± 
0.01
0.66 ± 
0.14
0.22 ± 
0.01
0.53 ± 
0.12
0.60 ± 
0.12
IgG2a 0.40 ± 
0.07
0.53 ± 
0.03
0.60 ± 
0.03
0.97 ± 
0.07
0.99 ± 
0.21
0.81 ± 
016
0.95 ± 
0.12
1.08 ± 
0.17
0.98 ± 
0.07
0.90 ± 
0.22
0.96 ± 
0.19
0.95 ± 
0.09
IgG2b 0.49 ± 
0.02
0.67 ± 
0.02
0.69 ± 
0.12
0.84 ± 
0.21
0.85 ± 
0.12
0.98 ± 
0.21
0.60 ± 
0.08
0.93 ± 
0.02
1.25 ± 
0.02
0.62 ± 
0.11
1.05 ± 
0.22
1.15 ± 
0.09
IgG3 0.31 ± 
0.03
0.39 ± 
0.12
0.40 ± 
0.12
0.20 ± 01 0.31 ± 
0.09
0.33 ± 
0.02
0.24 ± 
0.01
0.25 ± 
0.05
0.21 ± 
0.03
0.28 ± 
0.02
0.24 ± 
0.08
0.24 ± 
0.01
IgG2a,2b,2c and IgG3 were determined using ELISA in all the three bleeds for all the four peptides in different antigenic formulations using the 
isotyping kit. The O.D. values represent mean. ± SEM of four mice for the bleeds obtained on 27th (I), 42nd(II), and 60th (III) day.
Table 2: Measurement of KD value by EIA in high and low responder strains of mice. The binding affinities of the antibodies raised against 
different peptide formulations as assessed by EIA procedure. The slope of the lines (KD values) was calculated by the regression analysis.
Formulations → Peptide/
Strain ↓
25 µg peptide in Alum KD 
(nM)
5 µg Peptide DRV Alum KD 
(nM)
5:50 µg Peptide:MA729 
DRV Alum KD (nM)
5 µg peptide in ISCOMs KD 
(nM)
gp41/(BALB/c) 4.80 ± 0.05 1.30 ± 0.02 1.40 ± 0.02 2.70 ± 0.01
gp41/(CBA/J) 4.50 ± 0.10 1.50 ± 0.05 1.10 ± 0.01 6.70 ± 0.07
V3-gp41/(BALB/c) 0.20 ± 0.04 0.10 ± 0.01 0.05 ± 0.008 0.10 ± 0.02
V3-gp41/(CBA/J) 0.90 ± 0.03 0.40 ± 0.04 0.70 ± 0.03 0.50 ± 0.01
p17 /(FVB/J) 0.90 ± 0.06 0.40 ± 0.05 0.20 ± 0.01 0.50 ± 0.03
p17 /(BALB/c) 1.40 ± 0.05 0.10 ± 0.02 0.20 ± 0.02 0.90 ± 0.02
p24 /(BALB/c) 3.50 ± 0.02 0.60 ± 0.04 0.50 ± 0.01 0.60 ± 0.01
p24 /(CBA/J) 24.5 ± 0.18 5.49 ± 0.03 1.00 ± 0.03 2.50 ± 0.01
True affinity of the antibodies was measured for different peptides in second bleed of all the formulations. A fixed dilution of antisera (1:500) was 
used with various molar concentrations of peptide antigen (10-7 M - 10-10 M).
Table 1: IgG isotypes for mice of different haplotypes (H-2b, H-2k, H-2q, H-2d). Estimation of IgG isotypes for different peptide 
formulations in mice bearing haplotypes H-2b(1A), H-2k(1B), H-2q(1C), H-2d(1D). Levels of IgG1, IgG2a, IgG2b and IgG3 and 
determined as described in Materials and Methods at fixed antisera dilution (1:100). IgG2a,2b,2c and IgG3 were determined using ELISA 
in all the three bleeds for all the four peptides in different antigenic formulations using the isotyping kit. The O.D. values represent mean 
± SEM of sixteen mice (four for each haplotype) as studied for the bleeds obtained on 27th (I), 42nd(II), and 60th (III) day. (Continued)Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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Cell Mediated Immune Response
Though, most of the reported studies, antigen is immu-
nized in CFA/IFA for priming the spleen cells, in our
study, antigen was immunized in alum and taken as the
experimental group. Standardization of antigen induced T
cell proliferation was done using V3-gp41 peptide in alum
and 5 µg of peptide antigen in liposomes (with or without
50 µg MA729) or in ISCOMs. The optimum dose, which
showed the maximal T cell proliferation, was 50 µg/ml on
15th day with a single booster on 8th day. The above
immunization schedule was subsequently used for other
HIV peptides in different strains of mice under identical
set of conditions. Data was expressed in Stimulation Index
(SI).
T cell response to individual HIV-1 peptides
V3-gp41 peptide primed mice spleen cells when pulsed in
vitro with the homologous antigen showed a moderate
proliferation response in all the strains of mice (Fig
4A,4B,4C,4D). Stimulation with peptide in liposomes
induced moderately high T cell response (SI 9.7–17.6)
although the response was not statistically significant.
Haplotype H-2d responded slightly higher but insignifi-
cantly (P > 0.05) as compared to other haplotypes when
pulsed with the homologous antigen. Mice bearing the
haplotype H-2k (SI-36.8) and H-2d (SI 39.4) significantly
(P < 0.01) induced T cell proliferation compared to other
haplotypes in adjuvant/liposome and ISCOM formula-
tions. T cell response in Peptide-ISCOMs splenic cultures
when compared with peptide:MA729 formulation in lipo-
somes induced more or less similar SI and was statistically
insignificant. T-cell proliferation obtained after addition
of adjuvant MA729 along with V3-gp41 peptide (SI 22.3–
36.8) in liposomes or incorporated in ISCOMs (SI 18–
39.4) was the highest and was highly significant (P < 0.01)
as compared to spleen cells primed and pulsed with V3-
gp41 peptide alone or in liposomes.
For gp41 peptide all the haplotypes induced T cell stimu-
lation in a dose dependent manner with maximal prolif-
eration (SI-9.8–12.9) observed at 25 µg/ml for all the
haplotypes except H-2b  (Fig. 4E,4F,4G,4H). Liposome
preparation induced maximal T-cell stimulation of H-2b
haplotype as compared to H-2k,d&q  and addition of
adjuvant in liposomes along with peptide or in ISCOMs
led to antigen specific stimulation, with H-2k being the
strongest inducer. p17 peptide primed mice spleen cells
when pulsed in vitro with homologous antigen induced
moderate T cell proliferation in all the strains of mice
tested (SI-11.6–20.2) (Fig. 4I,4J,4K,4L). p17 peptide
produced comparative proliferative response when in
vitro stimulated with different concentrations of peptide
in liposomes for the haplotypes H-2k&q with the highest
and lowest responses observed for H-2d and H-2b respec-
tively. Surprisingly for p17 peptide inclusion of MA729
increased the T-cell stimulation (SI 18.4) only for mice
bearing the haplotype H-2q, with low stimulation
observed for haplotype H-2b,d&k (10.2–12.4). ISCOMs for-
mulation led to a good T cell response (SI-32.1–35.9)
which was statistically significant in mice bearing the hap-
Table 3: Immuno-reactivity of biotinylated HIV peptides derived from different clades using mice antisera against V3-gp41, gp41 and 
p17 peptides. Immunoreactivity of biotinylated HIV peptides using mice antisera raised against different HIV peptides. Titer of antisera 
was defined as the reciprocal of dilution which gave a mean absorbance of 0.5. Run was considered invalid if negative control gave a 
mean absorbance > 0.5.
Dilution of Antisera
Strain/Subtype Peptide Sequence 1:100 1:400 1:1600 1:6400 *Titer
Clade A NTRKSV-RIGPGQAF-Y 3.00 1.20 0.40 0.08 1348
Clade B NTRKSI-HIGPGRAF-Y 3.00 1.35 0.37 0.13 1318
Clade C NTRKSI-RIGPGQTF-Y 3.00 1.27 0.28 0.09 1148
Clade D NTRQRT-HIGPGQAL-Y 2.89 1.16 0.28 0.10 1122
Clade E NTRTSI-TRGPGQVF-Y 3.00 1.25 0.36 0.10 1258
Clade F NTRKSI-HLGPGQAF-Y 2.90 1.07 0.32 0.13 1148
Clade G NTRKSI-TIGPGQAF-Y 2.89 1.05 0.26 0.19 1023
MN Bio NKRKRI-HIGPGRAF-Y 2.90 0.91 0.24 0.12 933
SF2 Bio NTRKSI-YIGPGRAF-H 2.87 1.02 0.35 0.15 1148
BR1 NTRKSI-HIGWGRAF-Y 2.80 0.98 0.30 0.15 1047
BR2 NTRKSI-HMGW-GRAF-Y 2.64 0.96 0.28 0.16 1023
p17 YSVHQRIDIKETKDALEKIDDDNKSKKA 2.90 1.50 1.10 0.65 7000
gp41 DRPEGIEEEGERRDRDTS 2.90 2.80 1.80 1.0 7500
No Peptide - 0.12 0.05 0.06 0.04 11
* Titer of the antisera is defined as the reciprocal of dilution which gave a mean absorbance of 0.5. Run is considered invalid if negative control gave 
a mean absorbance ≥ 0.5.Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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lotypes H-2d&k (P < 0.01) and in mice of haplotype H-2b
(P < 0.01) or H-2q (P < 0.05) as compared to spleen cells
primed and pulsed with peptide alone or entrapped in
liposomes.
For p24 peptide, mice bearing the haplotype H-2q showed
the highest T-cell stimulation (SI-7.6) though statistically
insignificant (P > 0.05) than mice bearing the haplotypes
H-2b,d&k  when pulsed with homologous antigen (Fig.
4M,4N,4O,4P). However inclusion in liposomes led to
same degree of T-cell stimulation for all the haplotypes
studied. For p24 peptide adjuvant liposome constructs
maximal T cell response (SI-19.7 & 18.3) was obtained in
mice bearing the haplotypes H-2b&d which was highly sig-
nificant (P < 0.01) as compared to spleen cells pulsed and
primed with p24 peptide alone or in liposomes.
Entrapment in ISCOMs elicited significantly high T cell
proliferation (SI-13.4–15.6) (P < 0.05) as compared to
spleen cells primed and pulsed with p24 peptide studied
in all haplotypes.
T cell proliferation of peptides by cocktail approach
The T cell response for peptides in different formulations
was similar in both the haplotypes when studied by cock-
tail approach (Fig. 5A). In case of stimulation with pep-
tide in liposomes, V3-gp41 was found to induce the
maximum stimulation index in mice bearing the haplo-
type H-2k (SI-9.9) and in H-2d (SI-4.5) mice. With ISCOM
delivery of the stimulating peptide, the trend in stimula-
tion index was same but significantly higher for V3-gp41
(SI-18.7) and gp41 (SI-19.8) in H-2k  mice. Similarly,
inclusion of adjuvant along with peptide in liposomes
generated very high responses in both the haplotypes.
HIV plaque neutralization by serial dilutions of antibody Figure 3
HIV plaque neutralization by serial dilutions of antibody. Data were normalized as a percentage of the mean plaque count in 12 
replicate control wells which was 10.4 and 13.1 for V3-gp41 and gp41 peptides respectively.
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T cell proliferation of mice immunized with MA729
To look for the mitogenic activity of adjuvant MA729,
mice bearing the haplotype H-2d was immunized with 50
µg of the above adjuvant on day 0 and 8th and spleen cells
were subsequently harvested on day 15th (Fig. 5B). The
spleen cells were stimulated in vitro with V3-gp41 peptide
alone or in liposomes (with or without adjuvant) and
adjuvant MA729 (alone or in liposomes). Spleen cells
pulsed with V3-gp41 peptide (alone or in liposomes)
showed negligible levels of T cell stimulation with SI of
2.9 and 2.1 respectively. However stimulation with V3-
gp41 peptide along with adjuvant entrapped in liposomes
induced significantly high (P < 0.01) T cell stimulation
with SI of 8.3 as compared to response observed for
spleen cells pulsed with peptide alone or in liposomes.
Stimulation of MA729 primed spleen cells with MA729
alone or in liposomes also induced a very high T cell stim-
ulation with SI of 7.2 and 8.1 respectively indicating a
strong mitogenic activity of MA729, which is further
enhanced by inclusion in liposomes.
Estimation of Cytokines (IL-2, IFN-γ and IL-4)
Standard curves for IL-2 (0–1000 pg/ml), IFN-γ (0–12000
pg/ml), IL-4 (0–1000 pg/ml) were plotted and cytokines
were measured in culture supernatants obtained during T
cell stimulation assays (Table 4). The culture supernatants
obtained from spleen cells primed and pulsed with V3-
gp41 and gp41 peptides induced moderately high levels
of cytokines as compared to p17 and p24 peptides.
T-cell proliferation response for V3-gp41 (A-D), gp41 (E-H), p17 (I-L) and p24 (M-P) HIV-1 peptides Figure 4
T-cell proliferation response for V3-gp41 (A-D), gp41 (E-H), p17 (I-L) and p24 (M-P) HIV-1 peptides. Mice of different haplo-
types were primed with individual peptides and stimulated in vitro with peptide alone or in different antigenic formulations as 
described in materials and methods.
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Estimation of T-cell response using cocktail approach (A) for different HIV-1 peptides Figure 5
Estimation of T-cell response using cocktail approach (A) for different HIV-1 peptides. Mice were immunized with cocktail and 
in vitro stimulated with respective peptides alone or in adjuvant formulations. Effect of MA729 on T-cell stimulation in mice 
primed with adjuvant MA729 (B).
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Table 4: Cytokine levels for various peptides in different haplotypes. Cytokine levels as measured for various peptide formulations in 
different haplotypes. The value represents the level of cytokines obtained from wells pulsed with the optimal antigen (peptides alone 
or in adjuvant systems) concentration which showed maximal T-cell stimulation index).
Strain→ H-2 Haplotypes Cytokines (pg/ml)
Formulation↓ BALB/c
(H-2d)
CBA/J
(H-2k)
C57BL/6J
(H-2b)
FVB/J
(H-2q)
V3-gp41 Peptide 611 ± 21 311 ± 35 727 ± 68 878 ± 240 IFN-γ
372 ± 90 342 ± 28 2322 ± 245 260 ± 54 IL-2
29 ± 3 9.0 ± 1 35 ± 3 42 ± 6 IL-4
V3-gp41 in Liposomes 1076 ± 102 855 ± 44 1332 ± 221 1854 ± 132 IFN-γ
367 ± 35 408 ± 36 443 ± 24 475 ± 25 IL-2
19 ± 2 8.0 ± 2 40 ± 5 7.0 ± 1 IL-4
V3-gp41 in ISCOMs 1956 ± 145 2076 ± 126 2178 ± 231 2589 ± 321 IFN-γ
665 ± 42 757 ± 60 667 ± 32 660 ± 35 IL-2
12 ± 1 12 ± 2 36 ± 5 4.0 ± 1 IL-4
V3-gp41: MA729 in Liposomes 1856 ± 121 2325 ± 231 2560 ± 265 2667 ± 320 IFN-γ
821 ± 69 754 ± 58 702 ± 36 753 ± 36 IL-2
15 ± 5 13 ± 3 29 ± 5 18 ± 5 IL-4
gp41 Peptide 520 ± 56 655 ± 33 765 ± 36 333 ± 26 IFN-γ
200 ± 12 398 ± 25 390 ± 25 432 ± 20 IL-2
53 ± 5 32 ± 3 57 ± 6 41 ± 6 IL-4
gp41 Peptide in Liposomes 989 ± 65 1177 ± 125 1098 ± 89 980 ± 66 IFN-γ
445 ± 25 506 ± 55 535 ± 21 582 ± 32 IL-2
25 ± 6 15 ± 3 45 ± 5 7.0 ± 1 IL-4
gp41 Peptide in ISCOMs 1884 ± 155 1765 ± 211 1678 ± 201 2345 ± 315 IFN-γ
700 ± 36 814 ± 54 721 ± 58 765 ± 75 IL-2
15 ± 4 46 ± 5 52 ± 6 24 ± 3 IL-4
gp41 : MA729 in Liposomes 2577 ± 220 2436 ± 233 2245 ± 165 2100 ± 103 IFN-γ
789 ± 100 676 ± 20 723 ± 65 703 ± 87 IL-2
45 ± 6 32 ± 5 27 ± 8 40 ± 5 IL-4
p17 Peptide 433 ± 21 623 ± 12 453 ± 52 534 ± 31 IFN-γ
360 ± 21 183 ± 24 243 ± 34 253 ± 50 IL-2
20 ± 6 37 ± 3 29 ± 8 23 ± 6 IL-4
p17 Peptide in Liposomes 350 ± 30 786 ± 35 998 ± 53 1052 ± 32 IFN-γ
450 ± 27 387 ± 26 427 ± 32 364 ± 32 IL-2
30 ± 10 20 ± 4 51 ± 3 45 ± 6 IL-4
p17 Peptide in ISCOMs 677 ± 59 1321 ± 136 1200 ± 70 1400 ± 230 IFN-γ
618 ± 60 345 ± 32 627 ± 51 501 ± 34 IL-2
23 ± 4 23 ± 4 12 ± 4 57 ± 5 IL-4
p17 : MA729 in Liposomes 1756 ± 100 1899 ± 120 1500 ± 52 1876 ± 320 IFN-γ
489 ± 52 665 ± 50 603 ± 35 581 ± 18 IL-2
44 ± 13 41 ± 10 36 ± 5 39 ± 6 IL-4
p24 Peptide 435 ± 23 654 ± 36 500 ± 35 435 ± 35 IFN-γ
354 ± 29 385 ± 25 256 ± 23 334 ± 26 IL-2
18 ± 5 10 ± 2 34 ± 5 21 ± 8 IL-4
p24 Peptide in Liposomes 975 ± 63 987 ± 54 1123 ± 124 786 ± 69 IFN-γ
470 ± 56 235 ± 19 398 ± 54 402 ± 30 IL-2
29 ± 6 30 ± 3 22 ± 1 32 ± 4 IL-4
p24 Peptide in ISCOMs 1352 ± 69 1354 ± 54 1245 ± 103 1532 ± 301 IFN-γ
665 ± 80 478 ± 22 444 ± 31 676 ± 88 IL-2
13 ± 5 8.0 ± 6 19 ± 4 28 ± 4 IL-4
p24 : MA729 in Liposomes 1543 ± 56 1763 ± 240 1324 ± 99 1432 ± 26 IFN-γ
556 ± 40 600 ± 56 655 ± 87 543 ± 45 IL-2
23 ± 6 27 ± 4 38 ± 8 21 ± 7 IL-4
The value represents the level of cytokines obtained from wells pulsed with the optimal antigen (peptides alone or in adjuvant systems) 
concentration which showed maximal T-cell stimulation index.Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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Table 5: Cytokine levels for various peptide formulations by cocktail approach. Cytokine levels as measured for various peptide 
formulations generated by cocktail approach (The value represents the level of cytokines obtained from wells pulsed with the optimal 
antigen (peptides alone or in adjuvant systems) concentration which showed maximal T-cell stimulation index for mice primed with 
cocktail of peptides.
Strain→ H-2 Haplotypes Cytokines (pg/ml)
Formulation↓ BALB/c
(H-2d)
CBA/J
(H-2k)
V3-gp41 Peptide 623 ± 53 504 ± 29 IFN-γ
440 ± 19 291 ± 38 IL-2
41 ± 8 35 ± 4 IL-4
V3-gp41 in Liposomes 1100 ± 101 992 ± 63 IFN-γ
487 ± 21 321 ± 28 IL-2
70 ± 14 30 ± 2 IL-4
V3-gp41 in ISCOMs 1543 ± 165 1312 ± 287 IFN-γ
511 ± 28 360 ± 14 IL-2
60 ± 20 42 ± 9 IL-4
V3-gp41: MA729 in Liposomes 1210 ± 84 1413 ± 152 IFN-γ
489 ± 31 392 ± 30 IL-2
58 ± 2 58 ± 6 IL-4
gp41 Peptide 589 ± 54 623 ± 82 IFN-γ
401 ± 16 368 ± 41 IL-2
62 ± 11 48 ± 21 IL-4
gp41 Peptide in Liposomes 891 ± 16 924 ± 72 IFN-γ
519 ± 2 400 ± 21 IL-2
18 ± 54 32 ± 11 IL-4
gp41 Peptide in ISCOMs 937 ± 20 1321 ± 91 IFN-γ
521 ± 9 500 ± 48 IL-2
61 ± 156 51 ± 4 IL-4
gp41 : MA729 in Liposomes 1230 ± 19 1601 ± 134 IFN-γ
620 ± 10 635 ± 178 IL-2
20 ± 71 40 ± 2 IL-4
p17 Peptide 453 ± 31 368 ± 28 IFN-γ
301 ± 31 371 ± 18 IL-2
16 ± 3 20 ± 4 IL-4
p17 Peptide in Liposomes 1211 ± 96 892 ± 44 IFN-γ
520 ± 25 421 ± 28 IL-2
65 ± 9 30 ± 5 IL-4
p17 Peptide in ISCOMs 1135 ± 157 1031 ± 45 IFN-γ
520 ± 25 423 ± 21 IL-2
45 ± 5 31 ± 8 IL-4
p17 : MA729 in Liposomes 933 ± 28 1214 ± 76 IFN-γ
581 ± 34 408 ± 16 IL-2
53 ± 8 55 ± 7 IL-4
p24 Peptide 411 ± 40 284 ± 33 IFN-γ
387 ± 22 258 ± 19 IL-2
48 ± 7 54 ± 9 IL-4
p24 Peptide in Liposomes 989 ± 107 1123 ± 49 IFN-γ
460 ± 42 270 ± 29 IL-2
55 ± 6 34 ± 9 IL-4
p24 Peptide in ISCOMs 1007 ± 129 1290 ± 121 IFN-γ
508 ± 16 689 ± 43 IL-2
49 ± 8 36 ± 2 IL-4
p24 : MA729 in Liposomes 1241 ± 68 1334 ± 59 IFN-γ
500 ± 24 621 ± 26 IL-2
52 ± 7 41 ± 4 IL-4
The value represents the level of cytokines obtained from wells pulsed with the optimal antigen concentration (peptides alone or in adjuvant 
systems) which showed maximal T-cell stimulation index for mice primed with cocktail of peptides.Journal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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H-2d haplotype induced highest levels of IL-2 (372 ± 10.2
pg/ml) for V3-gp41 peptide. High levels of IL-2 were also
quantitated (390–445 pg/ml) in haplotypes H2 k,q&b for
gp41 peptide. The levels of IL-2 obtained for p17 and p24
peptides were also comparable within strain to strain
(183–360 pg/ml). In vitro stimulation with peptides
entrapped in liposomes was slightly higher and was found
to be statistically insignificant (P > 0.05). Highest levels of
IL-2 (489–821 pg/ml) were obtained in culture superna-
tants from spleen cells stimulated in vitro with pep-
tide:MA729 in liposomes. Haplotype H-2d responded the
best for all the peptides except p17, with V3-gp41 peptide
inducing the highest levels (821 ± 29 pg/ml). IL-2 levels
were found to be statistically higher (P < 0.01) when stim-
ulated in vitro with ISCOM formulations. Mice of halpo-
type H-2k responded best for V3-gp41 and gp41 peptides,
whereas H-2b and H-2q induced the highest stimulation
for p17 and p24 peptides respectively.
The production of IFN-γ in culture supernatants of V3-
gp41 and p17 primed and pulsed spleen cells were com-
parable and had low to moderately high levels of (311–
727 pg/ml) for the haplotypes H-2d,k&b whereas mice of
haplotype H-2q induced the highest levels (878 ± 28.9 pg/
ml) for V3-gp41 peptide. Moderately low levels of IFN-γ
were induced for gp41 and p24 peptide in all the haplo-
types studied. IFN-γ was substantially increased (786–
1362 pg/ml) when the cells were stimulated with peptide
entrapped in liposomes. The increase was however not
statistically significant (P > 0.05) as compared to stimula-
tion with homologous peptides except in haplotype H-2q
for gp41 peptide (P < 0.05). Significantly high levels were
observed in peptide:MA729 stimulated splenic cultures.
Inclusion of MA729 in liposomes significantly (P < 0.01)
enhanced the levels without any strain-to-strain variation.
Highest IFN-γ levels were detected in peptide ISCOMs
stimulated formulations. All the haplotypes produced
high levels of IFN-γ for all the peptides except for mice
bearing haplotype H-2d for p17 peptide.
Very low levels of IL-4 were induced for all the peptide for-
mulations and were comparable with the baseline levels
(27 ± 3.9 pg/ml) except for the liposome preparations
where IL-4 were found to be slightly above the base line
levels, but were in very low amounts as compared to other
cytokines (Table 4).
Estimation of cytokines by cocktail approach
Culture supernatants obtained from peptide primed
spleen cells stimulated in vitro with peptide in liposomes
induced high levels of IL-2 (337–492 pg/ml) (Table 5).
Higher levels of IL-2 were obtained for peptide entrapped
in ISCOMs (428–654 pg/ml). Spleen cells stimulated in
vitro with peptide entrapped along with MA729 in lipo-
somes induced the highest levels of IL-2 (389–635 pg/
ml). Low levels of IL-4 were induced (11–69 pg/ml for H-
2d & 17–61 pg/ml for H-2k) when the spleen cells were
pulsed in vitro with various peptide formulations. The lev-
els were comparable to the baseline levels. Peptide primed
spleen cells stimulated with peptide alone or entrapped in
liposomes (with or without MA729) or entrapped in
ISCOMs also induced very low levels of IL-2 in both the
haplotypes. The levels of IFN-γ were found to be higher for
V3-gp41 (623 ± 53 pg/ml) and gp41 (589 ± 54 pg/ml)
peptide as compared to p17 (453 ± 71 pg/ml) and p24
(411 ± 40 pg/ml) peptide. Peptide entrapped in lipo-
somes when used to pulse the spleen cells primed with
cocktail peptide in alum induced high levels of IFN-γ
(977–1089 pg/ml) for mice of haplotype H-2d as com-
pared to haplotype H-2k (933-89 pg/ml). This feature was
observed for all the peptides. Peptide entrapped in
ISCOMs also induced high levels of IFN-γ (1060–1543
pg/ml) for H-2d and (1031–1311 pg/ml) for H-2k. The
highest level of IFN-γ were obtained for V3-gp41 peptide
pulsed formulation in liposomes along with the adjuvant
(1601 ± 153 pg/ml) for the haplotype H-2k. IL-2 levels
when estimated in culture supernatants were found to be
higher for V3-gp41, gp41 and p17 peptides as compared
to p24 peptide. The levels were found to be same when
tested in both high and low responder strain.
Discussion
Peptides often elicit low-affinity antibodies and have lim-
ited ability to generate uniform immune response in an
outbred population. We demonstrate that the peptides
used in the present study were immunogenic in different
strains of mice tested with minimal strain-to-strain varia-
tion with the production of high affinity cytophillic anti-
bodies. V3-gp41 peptide was designed in such a way so
that there is synergistic effect of both the domains, activa-
tion of specific T cell help and neutralization of wild type
isolates. The study validates the superiority of hybrid pep-
tide sequences in accordance with the study in which syn-
thetic peptides containing T and B cell epitopes from HIV
env gp120 [peptide hybrid between V3 loop (303–321)
and T cell sequence (428–443)] [20] was used. Previous
report from our lab showed that a dimer of V3 loop or
gp41 peptide administered in CFA/IFA could induce high
antibody response [21]. Moreover recently we
demonstrate the role of polytuftsin in enhancing the
immunogenicity of HIV peptides [22]. The antibody
response to p17 peptide was lower as compared to enve-
lope peptides, but the pattern of response seen with differ-
ent delivery systems was more or less similar. p24 peptide
generated a relatively lower response as compared to the
other peptides studied. Several B-cell epitopes within this
region have been mapped including B-1 (KEPFRDYVD)
and B-2 (RFYKTLRAE) [23]. Thus HIV candidate vaccine
including gag  regions in addition to envelope proteins
might be more effective than those based on envelopeJournal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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region alone. All peptides when encapsulated in lipo-
somes or ISCOMs induced sustained antibody responses.
Similar results have also been reported by several other
authors in which encapsulation of protein/peptide anti-
gens with adjuvants in liposomes have led to induction of
strong antibody responses [24]. Several reports from our
lab also confirm these findings with CS protein of Plasmo-
dium vivax [25-27].
The adjuvant effect of ISCOMs is attributed to the pres-
ence of Quil A which brings about direct B cell activation,
which augments antibody responses against T cell inde-
pendent antigens [28]. ISCOMs containing natural or
recombinant palmitified gp120 has also shown to induce
ten times higher antibody titers as compared with CFA
[29,30].
The present study also demonstrates the elicitation of pro-
tective isotypes IgG2a and IgG2b against various peptide
formulations. Although alum adsorbed formulations are
known to produce IgG1 isotype during primary response
an additional IgG2a/2b response was stimulated. The
entrapment of peptides in aqueous compartments of lipo-
somes induces isotypes IgG2a and IgG2b [31] and the
presence of adjuvant [Thr1  MDP] and metabolizable
saponins such as Quil A enhances IgG2a production [32].
IgG2a subclass immunoglobulins are important in the
defense against virus infection in which opsonisation and
complement mediated lysis of virus and destruction of
virus-infected cells by ADCC may be of great importance.
IgG2a antibody is more effective than IgG1 antibody for
fixing complement [33]. It is also most effective subclass
for the activation of macrophages and natural killer cell
antibody dependent cellular cytotoxicity whereas IgG1
has very limited activity.
In the present study the determination of contribution of
individual components of cocktail peptide was done and
compared with the results obtained with single-antigen
immunization strategy which demonstrates a very good
example of peptide competition with MHC molecule in a
pool of sequences, picking up matched epitope with opti-
mal affinity rendering these two sequences highly immu-
nogenic. As a first step towards generation of vaccine
against HIV, we have demonstrated the efficacy of cocktail
of several of HIV synthetic peptides in the generation of
powerful humoral response using mice as an animal
model.
Generation of high affinity antibodies is of advantage as
they are more effective in virus neutralization. Both high
and low responder strains produced antibodies of compa-
rable affinity. When the antigen was administered along
with adjuvant, an inverse relationship was observed
between antigen dose and antibody affinity [34], which
correlates with our present findings, based on low dose
immunization. The findings are also well correlated with
the high affinity antibodies raised in CFA with protein
antigens as compared to delivery in saline. Adjuvants
influence affinity through process of cell selection by anti-
gen via effects on macrophages or directly preferentially
stimulating a particular subset of B cells which produce
high affinity antibody or enhance mutation in B cells to
produce receptors of high affinity [35].
The present study also demonstrates that env and gag pep-
tide constructs are capable of inducing neutralizing anti-
bodies, which are effective against lab-adapted, although
the effect on primary isolates was not studied which
would be interesting to perform. V3-gp41 peptide antise-
rum inhibited the formation of syncytia in both MT-2
cells. Antiserum raised against gp41 peptide (727–753)
inhibited the syncytia formation in both MT-2 and Sup-T1
cells. This may be attributed to interference in the virus
cell interactions as gp41 envelope antigen is involved in
membrane fusion following the binding of virions to the
CD4 receptor molecule. It is thus tempting to speculate
that anti-gp41 antibodies may therefore block viral cell
membrane interaction either at the cell surface or in the
endosomes.
We observed cross reactivity of mice antiserum to linear
V3-peptides from HIV clade B that is probably of limited
importance. Moreover HIV immune sera from many
sources appear to broadly cross-react with linear V3
sequences and this has not translated in to functional
antibody activity. Primary isolates are generally more
resistant to neutralization by immune antiserum and
monoclonal antibodies than laboratory adapted viruses
[36], although certain monoclonal antibodies can be
potent neutralizers of both types of viruses.
Cellular response
Cell mediated immunity, involving helper T cell and CTL
responses plays a crucial role in acute HIV infection. In
this study we have examined the potential enhancement
of cellular immunity against HIV-1 by immunomodulat-
ing the specific immune response to different synthetic
peptides derived from HIV antigens through the co-deliv-
ery of an adjuvant MA729. We present the immunogenic-
ity of synthetic peptide approach with immunoadjuvants
like MA729 for elicitation of cross-reactive T-cell prolifer-
ative responses. Moreover these immunogens induced
high tittered antibodies as described in the previous
section.
To investigate the cellular response to different peptide
sequences (V3-gp41, gp41, p17 and p24), four different
inbred strains of mice were immunized under identical setJournal of Immune Based Therapies and Vaccines 2003, 1 http://www.jibtherapies.com/content/1/1/5
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of conditions. The dose of peptide used for immunizing
animals was kept same as was used for studying the
humoral response. All mice of different haplotypes
showed higher in vitro T cell proliferation with peptides
V3-gp41 and gp41 as compared to p17 and p24 peptides
(Fig. 4). A study [37] has demonstrated in vitro that a gp41
peptide (584–609) that spans the entire length of our
gp41 peptide (589–609) had the potential to associate
spontaneously in vitro with diverse class I and class II HLA
molecules. Gp41 peptide (727–753) also provided good
degree of immunostimulation. It has been shown that the
region spanning residues 737–749 (GIEEEGGERDRDR)
stimulates PBMC's from HIV seropositive individuals and
acts as a strong T-cell epitope [38]. We reasoned that pep-
tides entrapped in liposomes (with MA729) or in ISCOMs
are able to stimulate T-cells of most haplotypes of mice
and hopefully also T-cells of humans of many HLA types.
As it was observed that the inclusion of adjuvant MA729
in liposomes with peptides significantly enhanced T-cell
stimulation, it highlights the mitogenic role associated
with the adjuvant for induction of strong T-cell prolifera-
tion responses. The observed effect of MA729 could be
linked to MDP, which is known to activate macrophages
and leukocytes [39], enhance chemotaxis and phagocyto-
sis [40,41] or by enhancing carrier specific T cell function.
ISCOM based vaccines have also been used and tested
with V3-loop peptide derived from HIV-2 for long stand-
ing protection against cell free HIV-2 [42]. The observa-
tion in the present work are in conformity with earlier
reports in which ISCOM borne antigen induced an
enhanced cell mediated response [43,44].
The results of cocktail studies obtained signifies the poten-
tial of V3-gp41 and p17 peptides as putative T cell
epitopes for induction of strong cell mediated immunity
as compared to gp41 and p24 peptides when tested by
cocktail approach.
Cytokine measurement
Cytokines play an important role in determining the out-
come of immune responses to infectious agents by differ-
entially affecting IgG isotype [45]. In the acute stage, Th1
like immune responses (IL-2 and IFN-γ) enhance cellular
immunity to control the infection whereas in the chronic
stage, Th2 immune responses (IL-4 and IL10) down regu-
late the effector immune responses, helping the organism
to persist in the body [46]. Also the balance between Th1
and Th2 activities determine the course of many infec-
tions [40].
The results obtained in the present study show that pep-
tide when entrapped in liposomes (with adjuvant) or in
ISCOMS induced higher levels of IFN-γ and IL-2 followed
by liposome preparations which induced moderate levels
of IFN-γ and IL-2, whereas all the peptides adsorbed on
alum alone produced low levels of IFN-γ and IL-2 (Table
4). IL-4 however when measured in culture supernatants
was detectable near the baseline levels. It is postulated
that peptide in liposomes may be activating cells of Th1
type resulting in high levels of IFN-γ and IL-2, as seen dur-
ing in vitro studies. MDP analog may be internalized by T
cells and stimulate the transcription of cytokine genes in
activated T cells. Culture supernatants from spleen cells
primed and pulsed with all the antigen preparation
showed elevated levels of IL-2, IFN-γ whereas IL-4 levels
seen were very low and were comparable to baseline
levels.
The secretion of IFN-γ by env and gag epitope stimulated
Th cells suggests that the formulation elicit Th1 like
immune responses. IFN-γ has also been shown to have
synergistic anti-HIV properties in vitro [48]. HIV env-trig-
gered release of these cytokines (IL-2 and IFN-γ) may be
beneficial in containing HIV-1 replication in vivo. Also,
preliminary evidence generated, in studies of vaccinated
non-human primates suggest that a vigorous Th cell
response including viral antigen specific IFN-γ production
may be an immune correlate of protection from HIV-1
and simian/human immune deficiency virus infection
[49].
One can imagine several strategies to skew the response to
a vaccine towards Th1 like responses with use of adjuvants
like MA729, which is correlated with earlier studies [50].
The findings are also well correlated with work carried out
previously in our lab in which linking of IL-1β [51] or pol-
ytuftsin to HIV peptides preferentially augmented Th1 like
response with induction of IFN-γ and IL-2.
The vaccine immunogen used in the present study has
been tailored to stimulate the most relevant response with
the use of chimeric V3-gp41 antigen and location of new
neutralization sites. In addition, the above approach
could be tested in non-human primates for protective effi-
cacy. Although this study doesn't provide definitive evi-
dence, it is however likely that the sequences tested may
bind promiscuously to different H-2 alleles and thereby
overcome MHC restriction.
Moreover, in view of the earlier findings that very low
doses of antigen preferentially induces DTH responses in
absence of antibody [52], it has been proposed that
immunization with low dose antigens might steer the
response towards a Th1 like pattern rather than Th2 like
pattern in the prophylactic vaccine against AIDS [53].
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